More than three many years after the identification of the human immunodeficiency virus (HIV), scientists are nonetheless working to develop a preventative vaccine that might lastly put an finish to the epidemic for which there are almost two million new infections every year.
In a brand new research, printed July 6 in The Lancet, a workforce of researchers led by Beth Israel Deaconess Medical Center’s Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research in collaboration with Janssen Vaccines & Prevention and different companions, evaluated a sequence of preventative HIV vaccine regimens in uninfected human volunteers in 5 nations. In a equally designed research, Barouch and colleagues examined the identical vaccine for its capacity to guard rhesus monkeys challenged with an HIV-like virus from an infection. The findings confirmed the vaccines induced strong and comparable immune responses in people and monkeys and guarded monkeys in opposition to acquisition of an infection.
“This study demonstrates that the mosaic Ad26/Ad26 plus gp140 vaccine candidate induced robust and comparable immune responses in human and monkeys,” mentioned Barouch, who can be Professor of Medicine at Harvard Medical School. “Moreover, the vaccine provided 67 percent protection against viral challenge in monkeys.”
Intended to offer broad safety from the numerous strains of HIV which are prevalent worldwide, the “mosaic” vaccine accommodates a patchwork of genetic sequences discovered amongst varied HIV strains. Known as APPROACH, the section 1/2a trial examined seven totally different Advert26/Env HIV vaccine regimens for his or her security, tolerability and the flexibility to elicit immune responses in 393 wholesome grownup volunteers in Rwanda, South Africa, Thailand, Uganda and the United States. All vaccine regimens had been well-tolerated and induced strong immune responses within the individuals.
“Based on these data, the mosaic Ad26/Env HIV-1 vaccine has been advanced into a phase 2b clinical efficacy study to determine whether this vaccine will prevent HIV infection in humans in southern Africa,” mentioned Barouch. “We expect results in 2021. This is only the 5th HIV vaccine concept that will be tested for efficacy in humans in the 35+ year history of the global HIV epidemic.”
The research is the results of a collaboration amongst researchers at BIDMC, Harvard Medical School and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard; the United States Military HIV Research Program (MHRP) on the Walter Reed Army Institute of Research (WRAIR); the National Institute of Allergy and Infectious Diseases (NIAID); the International AIDS Vaccine Initiative; the HIV Vaccine Trials Network (HVTN), Janssen Vaccines & Prevention B.V., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson; and a number of different companions.
Source: Beth Israel Deaconess Medical Center